No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.
CONCLUSIONS
Our results indicate that repeated treatment courses with tobramycin 10 mg/kg (twice daily for 3 weeks) may be safely applied in cystic fibrosis (CF) patients with respect to ototoxicity. The risk of hearing loss in this patient group is less than expected, which could be explained by either unfavourable baseline audiometry or the use of unidentified protective medication, or both. However, due to large inter-individual variations, audiometry screening remains important with respect to the detection of individual outliers.


OBJECTIVE
Tobramycin is frequently prescribed for CF patients. In this study, hearing loss due to cumulative tobramycin exposure in adult CF patients was investigated.


METHODS
We retrospectively investigated 19 patients with both baseline and follow-up audiometry before and after repeated courses of intravenous tobramycin (10 mg/kg/day in twice daily administrations for 3 weeks). Pure tone audiometry was performed at 0.250-16 kHz.


RESULTS
After repeated courses of tobramycin (median 3, range 1-8), the mean increase per frequency was 2.1 dB (median 0.5 dB, SD 12.6) with large (inter-individual) variations (range -23.5 to 34.5 dB). The pure tone averages (PTA) at 1-2-4 kHz and 8-10-12 kHz increased 1.4 dBHL and 2.3 dBHL, respectively, but were neither statistically significant, nor correlated with the cumulative tobramycin exposure.
Scheenstra
Renske J
RJ
Department of Otorhinolaryngology, Head and Neck Surgery, The Netherlands Cancer Institute, 1066 CXAmsterdam, The Netherlands. r.scheenstra@nki.nl
Heijerman
Harry G M
HG
Zuur
Charlotte L
CL
Touw
Daan J
DJ
Rijntjes
Evert
E
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006309:Hearing / Q000502:physiology*; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D014031:Tobramycin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D014031:Tobramycin